🇺🇸 IMM-101 in United States

24 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 24

Most-reported reactions

1. Cerebellar Infarction — 5 reports (20.83%)
2. Urinary Tract Infection — 5 reports (20.83%)
3. Dizziness — 3 reports (12.5%)
4. Blood Alkaline Phosphatase Increased — 2 reports (8.33%)
5. Haemoglobin Decreased — 2 reports (8.33%)
6. Red Blood Cell Count Decreased — 2 reports (8.33%)
7. Vomiting — 2 reports (8.33%)
8. Anaemia — 1 report (4.17%)
9. Biliary Sepsis — 1 report (4.17%)
10. Blood Creatinine Increased — 1 report (4.17%)

Source database →

Frequently asked questions

Is IMM-101 approved in United States?

IMM-101 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for IMM-101 in United States?

Immodulon Therapeutics Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.